Intellia Therapeutics Announces Closing of Initial Public Offering

Intellia Therapeutics (NTLA) News Today - MarketBeat

Citigroup reduced their price target on shares of Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research report on ...

Cell & Gene Therapy Commercial Insight – May 2016 - BioInsights

... Intellia Therapeutics closed its initial public offering raising net proceeds of just under $113 million. One of its close competitors, Editas Medicine ...

NTLA Stock Falls as Intellia Therapeutics Announces Public Offering

Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares.

Kyverna Therapeutics Announces Closing of Initial Public Offering ...

A registration statement relating to the offering has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on ...

Intellia Therapeutics Closes $690M Public Offering of Common Stock

CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. ... The gross proceeds raised in the offering, before underwriting ...

10-K - SEC.gov

INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its ... Company's common stock during the 30-day period prior to the closing. On ...

Intellia trumpets CRISPR drug data, but shares fall - Pharmaphorum

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase ...

Press Releases - Intellia Therapeutics - investor relations

Intellia Therapeutics Announces Closing of Initial Public Offering. Underwriters Exercise Over-Allotment Option CAMBRIDGE, Mass. , May 11, 2016 (GLOBE ...

CRISPR biotech Intellia strikes licensing deal with Regeneron ...

Regeneron will pay Intellia $75 million upfront, as well as investing $50 million in Intellia's forthcoming IPO. Additionally, the agreement ...

Intuit Inc. (via Public) / Preliminary Proxy Statement - Form PRE 14A

Company News. LM Funding America ... Intellia Therapeutics Inc. Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study[...].

CRISPR Therapeutics raises a $56M IPO, but patent battles ...

Switzerland and Cambridge, MA-based CRISPR Therapeutics priced its IPO at $14 a pop for 4 million shares, bringing home $56 million.

Endpoints News – Biotech and pharma business news, with a focus ...

Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis asset · Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges.

Intellia Therapeutics Reports Inducement Grants under Nasdaq ...

(NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced ...

STAT News

Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.

Intellia Therapeutics Announces Second Quarter 2024 Financial ...

CAMBRIDGE, Mass. , Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company ...

Intellia Therapeutics Announces First Quarter 2024 Financial ...

CAMBRIDGE, Mass. , May 09, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company ...

Press Releases - Intellia Therapeutics - investor relations

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy ...

Press Releases - Intellia Therapeutics - investor relations

Intellia Therapeutics Announces Closing of $115 Million Public Offering of ... Intellia Therapeutics Announces First Quarter 2020 Financial Results. On ...

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 ...

(NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based ...

Aerovate Therapeutics Announces Closing of Initial Public Offering ...

BOSTON, July 02, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs ...